Cytokinetics, Incorporated (NASDAQ: CYTK) is a Healthcare company (Biotechnology) with a market capitalization of $7.2B. The Maz Rating grades it against the other companies in its sector.
Cytokinetics, Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $51.65, Cytokinetics, Incorporated trades at 63.4x sales. Over the last twelve months it generated about $114M of revenue and a net loss of $842M. It runs a gross margin of 91.0%, an operating margin of -625.2% and a net margin of -686.6%. It shows return on equity of 157.1%, return on invested capital of -42.5% and a free cash flow yield of -8.2%. On the balance sheet: a debt-to-equity ratio of -3.96 and a current ratio of 3.36. Over the past 52 weeks the share price ranged from $51.38 to $88.31, with a beta of 0.36.
Cytokinetics, Incorporated does not currently pay a dividend.
35 Wall Street analyst ratings cover the stock: 34 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cytokinetics, Incorporated (CYTK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.0% / 30% · Interest income / Revenue 33.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 13.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.8% / 33% · Receivables / Mkt Cap (36m) 0.38% / 49% · Interest income / Revenue 33.4% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 13.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.8% / 33.33% · Receivables / Mkt Cap (24m) 0.38% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 71.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 62.0% / 33.33% · Receivables / Avg Assets (4Q) 1.29% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
| FTSE | Debt / Total Assets 63.1% / 33.33% · (Cash+ST Inv) / Total Assets 61.9% / 33.33% · (Cash+Recv) / Total Assets 63.8% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
No. As of September 2026, Cytokinetics, Incorporated (CYTK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cytokinetics, Incorporated is over the AAOIFI limit on Interest income / Revenue.
About 33.4% of each dividend: Cytokinetics, Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.